Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Metastatic Solid Tumors 1 Breast Neoplasms 1

Interventions

Sorafenib 10 Magnetic Resonance Spectroscopy 10 trametinib 8 lenvatinib 8 dabrafenib 7 pembrolizumab 6 Nivolumab 6 Iodine-131 6 Everolimus 6 Sunitinib 5 Paclitaxel 5 vandetanib 4 apatinib 4 Thyrotropin Alfa 4 Doxorubicin 4 selpercatinib 3 anlotinib 3 Specimen Handling 3 Radiotherapy 3 Ipilimumab 3 Iodine-124 3 Fluorodeoxyglucose F18 3 Cisplatin 3 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3 tislelizumab 2 tipifarnib 2 surufatinib 2 spartalizumab 2 pazopanib 2 omipalisib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Thyroid Neoplasms × Antibodies, Bispecific × Clear all

NCT00467506 2011-11-11

RIT in MTC

Nantes University Hospital

Phase 2 Completed

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡